Cambridge, MA, Sept. 26, 2024 –Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced today that Fierce Life Sciences and Fierce Healthcare have named Insilico Medicine as one of 2024’s Fierce 50 honorees. The Fierce 50 showcases 50 individuals and companies driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare.
“The annual Fierce 50 special report highlights individuals and companies that are driving progress in the pharmaceutical, healthcare and biotechnology industries,” said Ayla Ellison, Editor-in-Chief of Fierce Life Sciences and Healthcare. “These 50 outstanding organizations and people demonstrate excellence in their fields, and their commitment to innovation, equity and improving lives is truly commendable. Congratulations to this year’s honorees.”
Founded in 2014, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico keeps integrating technical breakthroughs into the Pharma.AI platform, which is currently a generative AI-powered solution spanning across biology, chemistry and clinical development. Powered by Pharma.AI, Insilico has nominated 20 preclinical candidates in its comprehensive portfolio of over 30 assets of which 9 molecules have received IND approval.
In early 2024, Insilico published a Nature Biotechnology paper presenting the entire R&D journey from AI algorithms to Phase II clinical trials of ISM001_055, the company’s lead asset, with an AI-discovered target and AI-designed structure. Following that, Insilico has recently announced positive preliminary results from a Phase IIa trial (NCT05938920), where ISM001_055 showed favorable safety and tolerability across all dose levels, as well as dose-dependent response in forced vital capacity (FVC), after only 12 weeks of dosage.
“We are incredibly honored to be named one of the 2024 Fierce 50, following our previous recognition as a Fierce 15 honoree by Fierce Medtech in 2019,” Said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. “This prestigious recognition is a testament to Insilico's relentless innovation in AI-driven drug research and development. It further inspires our team to leverage advanced generative AI technology and robotics to accelerate the creation of innovative therapies for patients with unmet medical needs worldwide.”
The Fierce 50 is a constellation of the most brilliant visionaries and trailblazers, handpicked by the discerning editors of Fierce Biotech, Fierce Pharma and Fierce Healthcare. These individuals and companies are a driving force in healthcare delivery, drug development, research, and more. The Fierce 50 honorees will be honored live at an evening gala at the Lighthouse at Pier Sixty One in New York on December 5th. For more information visit https://fierce50.fiercelifesciences.com/.
About Insilico Medicine
Insilico Medicine, a global clinical-stage biotechnology company powered by generative AI, connects biology, chemistry, and clinical trial analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to assist novel target discovery and the generation of novel molecular structures. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com